An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin

Pernicious anaemia (PA) is an autoimmune condition where antibodies target intrinsic factor and parietal cells, reducing the patient’s ability to absorb cobalamin promoting atrophic gastritis. Treatment guidelines are based on excretion data of hydroxocobalamin from healthy individuals obtained 50 y...

Full description

Saved in:
Bibliographic Details
Main Authors: T. R. Elliott, A. L. Guildford
Format: Article
Language:English
Published: Wiley 2017-01-01
Series:International Journal of Inflammation
Online Access:http://dx.doi.org/10.1155/2017/5968618
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832554347912757248
author T. R. Elliott
A. L. Guildford
author_facet T. R. Elliott
A. L. Guildford
author_sort T. R. Elliott
collection DOAJ
description Pernicious anaemia (PA) is an autoimmune condition where antibodies target intrinsic factor and parietal cells, reducing the patient’s ability to absorb cobalamin promoting atrophic gastritis. Treatment guidelines are based on excretion data of hydroxocobalamin from healthy individuals obtained 50 years ago. This manuscript describes the use of phorbol 12-myristate 13-acetate (PMA) to stimulate low grade inflammation in an epithelial colorectal cell line to assess the efficacy of methylcobalamin and hydroxocobalamin. Nitric oxide increased significantly in cells exposed to higher doses of PMA (100 ng/ml, 150 ng/ml, and 200 ng/ml) accompanied by a loss of the characteristic cobblestone morphology with no negative effect on cell activity or viability. A significant reduction in nitric oxide production was associated with the addition of 200 pg/ml hydroxocobalamin, alongside a return to the characteristic cobblestone morphology. This study highlights the use of PMA to promote low grade inflammation in human cell lines to model gastric inflammation associated with autoimmunity; furthermore it raises questions regarding the concentration of cobalamin administered clinically to restore cell functionality, feasibly allowing the patient to receive reduced quantity of the vitamin more regularly, providing the patient with levels which are akin to dietary intake.
format Article
id doaj-art-3258260a28f64e79b6a52fc9bbe25d23
institution Kabale University
issn 2090-8040
2042-0099
language English
publishDate 2017-01-01
publisher Wiley
record_format Article
series International Journal of Inflammation
spelling doaj-art-3258260a28f64e79b6a52fc9bbe25d232025-02-03T05:51:44ZengWileyInternational Journal of Inflammation2090-80402042-00992017-01-01201710.1155/2017/59686185968618An In Vitro Model of Gastric Inflammation and Treatment with CobalaminT. R. Elliott0A. L. Guildford1Brighton Studies in Tissue-Mimicry and Aided Regeneration (BrightSTAR), Brighton Centre for Regenerative Medicine, School of Pharmacy and Biomolecular Sciences, University of Brighton, Lewes Road, Brighton BN2 4GJ, UKBrighton Studies in Tissue-Mimicry and Aided Regeneration (BrightSTAR), Brighton Centre for Regenerative Medicine, School of Pharmacy and Biomolecular Sciences, University of Brighton, Lewes Road, Brighton BN2 4GJ, UKPernicious anaemia (PA) is an autoimmune condition where antibodies target intrinsic factor and parietal cells, reducing the patient’s ability to absorb cobalamin promoting atrophic gastritis. Treatment guidelines are based on excretion data of hydroxocobalamin from healthy individuals obtained 50 years ago. This manuscript describes the use of phorbol 12-myristate 13-acetate (PMA) to stimulate low grade inflammation in an epithelial colorectal cell line to assess the efficacy of methylcobalamin and hydroxocobalamin. Nitric oxide increased significantly in cells exposed to higher doses of PMA (100 ng/ml, 150 ng/ml, and 200 ng/ml) accompanied by a loss of the characteristic cobblestone morphology with no negative effect on cell activity or viability. A significant reduction in nitric oxide production was associated with the addition of 200 pg/ml hydroxocobalamin, alongside a return to the characteristic cobblestone morphology. This study highlights the use of PMA to promote low grade inflammation in human cell lines to model gastric inflammation associated with autoimmunity; furthermore it raises questions regarding the concentration of cobalamin administered clinically to restore cell functionality, feasibly allowing the patient to receive reduced quantity of the vitamin more regularly, providing the patient with levels which are akin to dietary intake.http://dx.doi.org/10.1155/2017/5968618
spellingShingle T. R. Elliott
A. L. Guildford
An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
International Journal of Inflammation
title An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
title_full An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
title_fullStr An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
title_full_unstemmed An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
title_short An In Vitro Model of Gastric Inflammation and Treatment with Cobalamin
title_sort in vitro model of gastric inflammation and treatment with cobalamin
url http://dx.doi.org/10.1155/2017/5968618
work_keys_str_mv AT trelliott aninvitromodelofgastricinflammationandtreatmentwithcobalamin
AT alguildford aninvitromodelofgastricinflammationandtreatmentwithcobalamin
AT trelliott invitromodelofgastricinflammationandtreatmentwithcobalamin
AT alguildford invitromodelofgastricinflammationandtreatmentwithcobalamin